Experts discuss persistent CMV challenges and new antiviral approaches for transplant patients
In a recent episode of BioSpace's Denatured podcast, Ian McGowan, chief medical officer of Synklino, and James Hunter, an associate professor of transplantation at Oxford University, joined host Jennifer C. Smith-Parker to talk about cytomegalovirus in transplant care.
The guests described CMV as one of the most stubborn and high-impact infections that can affect patients after organ transplantation, noting its ongoing impact on morbidity and mortality.
The conversation turned to emerging antiviral innovations and the need for better prevention strategies, but no specific drug approvals or clinical trial data were disclosed.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “Rewriting the rules of CMV prevention”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that